Physician profile
Robert L Mims
NPI 1851303135
$6,994.13
in general payments reported to CMS, 2019-2025
12 companies · $1,519 in 2025
The $1,519 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,423 · 2020: $131 · 2021: $1,086 · 2022: $804 · 2023: $1,044 · 2024: $987 · 2025: $1,519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,439 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,438.59 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,007.96 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $1,385.96 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $903.63 | 2020-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $609.10 | 2019-2023 | Lybalvi, Aristada |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $507.13 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $469.18 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $355.72 | 2019-2024 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $307.29 | 2025 | Cobenfy |
| Indivior INC. | $167.07 | 2019-2023 | Perseris |
| Lundbeck LLC | $161.23 | 2023-2025 | Abilify Asimtufii, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $109.05 | 2019-2023 | Hetlioz, Fanapt |
| Allergan, INC. | $10.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mims listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.